**Table 1. Differential expressions of SMA, Caveolin1, Cyclin B, Cyclin E, LMP2, NT5DC2, CD133, and Ki-67 in human uterine mesenchymal tumors and uterine LANT-like tumor.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Mesenchymal tumor types** | **Age**  **years** | **n** | **Protein expression**\* | | | | | | | |
| **SMA** | **CAV1** | **CCNB** | **CCNE** | **LMP2** | **NT5DC2** | **CD133** | **Ki-67** |
| **Normal** | 30s-80s | **74** | +++ | - | - | - | +++ | - | - | - |
| **Leiomyoma (LMA)**  (Ordinally leiomyoma)  (Cellular leiomyoma) | 30s-80s | **40**  (30)  (10) | +++ | ++ | -/+ | -/(+) | +++ | -/+ | - | +/- |
| +++ | ++ | -/+ | - | +++ | -/+ |  | +/- |
| ++ | ++ | -/+ | -/(+) | ++ | -/+ |  | +/- |
| **STUMP** | 40s-60s | **12** | ++ | ++ | + | -/+ | -/+ | -/+ | NA | +/+++ |
| **Bizarre Leiomyoma** | 40s-50s | **4** | ++ | ++ | -/+ | + | Focal+ | + | NA | + |
| **Intravenous LMA** | 50s | **3** | ++ | ++ | + | + | - | NA | ++ | + |
| **Benign metastasizing** | 50s | **1** | ++ | ++ | + | ++ | - | NA | NA | ++ |
| **Leiomyosarcoma** | 30s-80s | **54** | -/+ | + | ++ | +++ | -/+ | ++ | ++ | ++/+++ |
| **Rhabdomyosarcoma** | 10s,50s | **2** | NA | ++ | -/+ | +++ | +++ | NA | NA | NA |
| **U.LANT**#**-like tumour** | 40s | **1** | ++ | + | NA | ++ | - | NA | NA | - |

\*Staining score of expression of SMA, CAV1 (Caveorin 1), CCNB (Cyclin B), CCNE (Cyclin E), LMP2 (low molecular protein 2), NT5DC2 (5'-Nucleotidase Domain Containing 2) and Ki-67 from results of IHC experiments. Protein expression\*; estimated-protein expressions by immunoblot analysis, immunohistochemistry (IHC) and/or RT-PCR (quantitative-PCR),-/+; partially positive (5% to 10% of cells stained), Focal+; Focal-positive (focal or sporadic staining with less than 5% of cells stained),++; staining with 5% or more, less than 90% of cells stained, +++; diffuse-positive (homogenecus distribution with more than 90% of cells stained), -; negative (no stained cells). U.LANT-like tumour; uterine leiomyomatoid angiomatous neuroendocrine tumour-like tumour, LMP2 (ref.21,22,23), cyclin E(ref.21,23), caveolin1(ref.24), NT5DC2(ref.25), CD133(ref.9), Ki-67(ref.22,23). STUMP (Smooth muscle tumor of uncertain malignant potential) (ref.26,27). Cyclin E, LMP2, Caveolin1 are potential biomarker for human uterine mesenchymal tumors. LANT#, leiomyomatoid angiomatous neuroendocrin tumour (LANT) is described as a dimorphic neurosecretory tumor with a leiomyomatous vascular component (ref.28). NA; no answer.